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A b s t r a c t
Introduction: Drug-eluting stents of the first (DES I) and second generation (DES II) proved superior to bare metal stents (BMS) in 
the coronary territory. However, there are limited data on whether they have any advantage over BMS in vertebral artery stenosis (VAS).
Aim: To compare outcomes of DES (DES I, DES II) and BMS in the treatment of symptomatic extracranial VAS.
Material and methods: During 13-year study period (2003–2016), 392 consecutive patients underwent VAS angioplasty in 428 
arteries, including implantation of 148 DES (DES I: 21; DES II: 127 lesions), and 280 BMS.
Results: The technical success rates for DES and BMS groups were 96.7% and 94.6% (p = 0.103), with similar periprocedural 
complication rates (1.4% vs. 2.2%; p = 0.565). VAS degree was reduced from 86 ±9.7 to 2.7 ±5.0% in DES (p < 0.001) and from 84.1 
±9.4 to 4.3 ±6.9% in BMS (p < 0.001). Angiography confirmed in-stent restenosis/occlusion (ISR/ISO) 50–99% in 53 (14.2%) and 
21 (5.6%) out of 373 patients (409 arteries) with at least 6-month follow-up. ISR/ISO rates were similar in DES vs. BMS (22.8% vs. 
19.4%; p = 0.635), as well as in DES I vs. DES II (6/19; 31.6% vs. 25/92; 27.2%, p = 0.325). Stainless steel (24/135; 17.8%) and co-
balt-chromium (23/121;19%) BMS had significantly lower incidence of ISR/ISO, as compared to platinum-chromium (7/18; 38.9%), 
p = 0.034. ISR/ISO was associated with age (p = 0.01) and CRP level > 5 mg/l (p = 0.043), while greater stent length was associated 
with ISR only in the DES group (p = 0.024).
Conclusions: Our results do not support significant differences in ISR/ISO rates between DES and BMS, although differences 
between particular stent types and ISR rates require further investigation.
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S u m m a r y
To date, in contrast to the coronary territory, there are few data regarding comparison of drug-eluting stents (DES) and 
bare metal stents (BMS) in vertebral artery stenosis (VAS). In our study, we compared DES (first and second generation) and 
BMS in the treatment of symptomatic extracranial VAS during a 13-year period. The results do not support significant dif-
ferences in in-stent restenosis/in-stent occlusion (ISR/ISO) rates between DES and BMS in the long-term follow-up, although 
differences between particular stent types and ISR rates require further investigation.
Introduction
The origin and the V1 segment of the vertebral 
artery (VA) are a  common site for atherosclerotic oc-
clusive disease, and they constitute the second most 
frequent atherosclerosis involvement in the territory of 
the large supra-aortic arteries, just behind the internal 
carotid artery location [1–3]. VA lesions lead to signs 
and symptoms of posterior fossa ischemia (PFI), with 
significant morbidity and mortality, which may be as 
high as 30% [4].
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Of note, one-quarter of ischemic strokes are located 
in the vertebra-basilar territory (VBT) and around 20% of 
posterior circulation strokes occur in the setting of extra-
cranial vertebral artery stenosis (VAS) [2]. In addition, pa-
tients experiencing VBT transient ischemic attacks (TIAs) 
have a 25% to 35% risk of stroke within 5 years [5].
The optimal therapeutic management of extracranial 
VAS is debatable [5]. Three potential methods of treat-
ment are available, medical therapy, surgical reconstruc-
tion, and endovascular interventions, but no clear indica-
tions have been established [3]. Medical treatment with 
antiplatelet agents and vasodilators is widely accepted in 
patients with symptomatic VAS [6]. 
If symptoms persist, invasive methods of treatment 
can be used [3]. Open vascular surgery includes endarter-
ectomy, surgical bypass, and carotid-vertebral transposi-
tion in referential centers with satisfactory results have 
been reported [6]. However, with the increasing develop-
ment of endovascular device technology, percutaneous 
angioplasty of VAS has become an alternative option to 
surgery [3, 7], with provisional stent implantation that 
favors the short- and long-term outcome in comparison 
to balloon angioplasty alone [8]. 
The real milestone of endovascular interventions was 
introduction of drug-eluting stents (DES), initially the first 
(DES I), and then the second generation (DES II), which in 
the coronary territory were found superior to bare metal 
stents (BMS) [9, 10]. However, there are limited data indi-
cating whether DES I and DES II have any advantage over 
BMS in the posterior circulation territory, namely VAS. 
Aim
Therefore, the main objective of the present study 
was to evaluate the immediate and long-term outcome 
of endovascular VAS procedures performed at our insti-
tution between 2003 and 2016 in respect of safety and 
long-term efficacy with special regard to different stent 
types used. Also, we aimed to identify potential risk fac-
tors associated with stenosis recurrence (stent patency). 
Material and methods
The registry is a consecutive series of patients with 
signs and symptoms of PFI seen at our institution, in 
whom stent-supported angioplasty was performed 
during a  13-year period (between the years 2003 and 
2016). Written informed consent was obtained from all 
patients and the study was approved by the local ethics 
committee, and the study was conducted in compliance 
with the Declaration of Helsinki. 
Of the 392 consecutive patients in the registry, 428 
endovascular procedures with stent implantation were 
performed for V0-V1 segment lesions.
Group I comprised 280 lesions covered with BMS in 
270 patients (195; 72.2% male), with the mean age of 
67.5 ±8.6 years.
Group II comprised 148 lesions covered with DES in 
144 patients (98; 68.1% male), with the mean age of 
66.6 ±8.5 years. Group II was additionally subdivided into 
subgroups of patients who had DES I  (21 lesions) and 
DES II implantation (127 lesions). 
Detailed study groups characteristics, as well as in-
dications for the endovascular treatment, are presented 
in Table I. In brief, inclusion criteria for revascularization 
were either symptomatic patients with at least 60% lu-
men diameter stenosis or patients who underwent en-
dovascular treatment of symptomatic subclavian artery 
disease complicated by a plaque shift with subsequent 
significant flow limitation in the vertebral artery requir-
ing VA stenting. All patients underwent neurological 
examination by a  site neurologist prior to VA stenting 
procedure, and re-assessment before hospital discharge. 
Collected information included demographics, risk fac-
tors, clinical description of symptoms, neurologic deficits, 
and results of diagnostic testing.
Endovascular procedure
One day before the procedure, patients received 
a 300 mg loading dose of clopidogrel, followed by 75 mg 
o.d. for 1 month after BMS and 6–12 months after DES 
implantation. Patients were on aspirin 75 mg o.d., which 
was continued indefinitely afterwards.
Access to VA was obtained through a femoral or radial 
approach with a 6 Fr sheath, as determined by the patient’s 
anatomy. During VA stenting procedures all patients were 
monitored for vital parameters and neurologically.
After the artery cannulation, heparin was given to 
achieve an activated coagulation time of 250 to 300 s. 
Over a 0.035-inch diagnostic wire a 6 Fr guiding cathe-
ter was advanced toward the VA ostium. Then the lesion 
was crossed with a 0.014 inch coronary guide wire. All 
VA stenting procedures were unprotected. Direct stent-
ing was performed when possible and the stent type was 
within the individual responsibility of each intervention-
ist (Figures 1 A–C). The old-generation DES cohort includ-
ed sirolimus (n = 14) and paclitaxel (n = 7) eluting stents 
and the second-generation DES group included everoli-
mus (n = 57), biolimus (n = 35) and zotarolimus (n = 36) 
eluting stents (Table II). BMS included cobalt-chromium 
(n = 123), stainless steel (n = 139) and platinum-chromi-
um (n = 18).
Before and after stent deployment, the degree of 
stenosis was calculated with quantitative angiography. 
Technical success was defined as post-interventional re-
sidual stenosis < 30%.
Patients’ follow-up
Clinical performance and complications within 30 
days, in-stent restenosis/occlusion (ISR/ISO) and overall 
survival were compared between DES and BMS groups. 
Clinical success was defined as technical success with 
Damian R. Maciejewski et al. DES vs. BMS for extracranial VA stenting
330 Advances in Interventional Cardiology 2019; 15, 3 (57)
resolution of vertebro-basilar insufficiency (VBI) symp-
toms.
Vascular imaging included carotid and vertebral ar-
tery duplex ultrasonography (DUS) or computed tomog-
raphy angiography (CTA) in all patients performed before 
discharge, at 6 and 12 months, and then every year on 
outpatient visits, and conventional angiography if reste-
nosis was suspected.
Repeated angiography was performed if in-stent 
restenosis/in-stent occlusion (ISR/ISO) was suspected 
on a noninvasive image combined with the presence of 
recurrent symptoms. In-stent restenosis was defined as 
a diameter stenosis ≥ 50% in the stented artery (Figures 
1 D–G).
Incidence rates of major adverse cerebral and coro-
nary event (MACCE), cardiovascular death or any death 
were recorded during the follow-up period. Data on 
MACCE were collected during the ultrasound visits. The fi-
nal closing visit was done through telephone contact with 
a  patient or an appointed family member. For patients 
lost to follow-up, the data on whether the patients were 
alive were obtained from the national health registry.
Statistical analysis
Comparisons between groups was made with Stu-
dent’s t-test, one-way analysis of variance or the c2 test 
as appropriate.
Continuous variables are presented as the mean 
± standard deviation, and categorical variables are ex-
pressed as the counts (percentages). Survival analysis 
included Kaplan-Meier plots, and comparison of survival 
in two or more samples was made for events. 







Age [years] 66.6 ±8.5 67.5 ±8.6 0.080
Men, n (%) 98 (68.1) 195 (72.2) 0.375
Comorbidities, n (%):
Coronary artery disease 89 (61.8) 149 (55.2) 0.194
Previous myocardial infarction 41 (28.5) 72 (26.7) 0.694
Previous percutaneous coronary intervention 43 (29.9) 69 (25.6) 0.348
History of coronary artery bypass grafting 15 (10.4) 36 (13.3) 0.389
Previous carotid artery stenting 34 (23.6) 56 (20.7) 0.500
Carotid artery occlusion 32 (22.2) 73 (27) 0.284
Previous percutaneous transluminal angioplasty in peripheral vascular 
disease
6 (4.2) 17 (6.3) 0.367
Previous carotid endarterectomy 8 (5.6) 7 (2.6) 0.124
Hypertension 138 (95.8) 268 (99.3) 0.016
Dyslipidaemia 133 (92.4) 264 (97.8) 0.008
Diabetes mellitus 45 (31.3) 69(25.6) 0.217
Insulin therapy 15 (10.4) 26 (9.6) 0.798
Symptomatic peripheral artery disease 32 (22.2) 53 (19.6) 0.533
Indications for treatment, n (%):
Vertigo, dizziness 136 (94.4) 252 (93.3) 0.657
VBS stroke 65 (45.1) 114 (42.2) 0.568
VBS TIA 35 (24.3) 65 (24.1) 0.958
Occipital lobe stroke 15 (10.4) 26 (9.6) 0.798
Recurrent syncope 25 (17.4) 55 (20.4) 0.460
Tinnitus 1 (0.7) 4 (1.5) 0.485
Continuous data are presented as the mean ± standard deviation; categorical data are given as the count (percentage).
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Data were analyzed in two groups: DES vs. BMS or 
DES I vs. DES II vs. BMS.
The potential independent prognostic markers of ISR 
during the follow-up period were established from the 
10 variables with a  univariate analysis. In the case of 
p < 0.1 they were entered into a multivariate Cox propor-
tional hazard analysis model. The results of the multi-
variate logistic regression analysis were expressed as the 
hazard ratio (HR) and 95% confidence interval (95% CI).
Statistica version 12 (StatSoft Poland) was used to 
analyze data. P-value < 0.05 was considered statistically 
significant.
Results
In the study period between April 2003 and January 
2016, 392 consecutive patients underwent VA stenting 
in 428 arteries, including implantation of DES in 144 pa-
tients, and BMS in 270 patients. 
Subjects in the BMS group, as compared to DES 
group, had higher prevalence of hypertension (p = 0.016) 
and hyperlipidemia (p = 0.008), whereas there were no 
significant differences with respect to the cardiovascular 
history and atherosclerosis risk factors as well as symp-
toms of PFI. The detailed clinical characteristics are sum-
marized in Table I.
Figure 1. A  – Right vertebral artery critical stenosis (white arrow).  
B – Balloon post-dilatation after balloon-expandable Multi-Link Vision 
(BMS – cobalt-chromium; Abbott) 3.5 mm × 12 mm direct stenting.  
C – Final angiography showing optimal effect of VA stenting. D – An-
giography confirming in-stent restenosis (white arrow). E – Sprinter 
(Medtronic) 3.0 mm × 15 mm balloon pre-dilatation. F – Dior (Eurocor) 
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In 36 (9.2%) patients bilateral VA stenting was per-
formed, whereas in the remaining 2 patients, 2 stents to 
V0 and V1 segments of the same artery were implanted. 
In all cases of double stenting, the DES was used. There 
were no patients with isolated VA take-off from the aor-
tic arch.
Fifteen (3.8%) patients underwent endovascular 
treatment of symptomatic subclavian artery disease on 
the same session, including 2 patients with significant 
symptomatic plaque shift causing obstruction of the VA 
origin. 
Detailed study procedure technique and stent types 
are presented in Table II. In brief, the stenosis degree was 
reduced from 86 ±9.7 to 2.7 ±5.0% in the DES group and 
from 84.1 ±9.4 to 4.3 ±6.9% in the BMS group (p < 0.001). 
The technical success rate was 96.7% for DES and 94.6% 
for BMS group (p = 0.103). The PFI symptoms resolved in 
90.3% and 92.2% of patients in the DES and BMS cohort, 
respectively (p = 0.739).
Periprocedural complications occurred in 2 (1.4%) 
and 6 (2.2%) subjects in the DES and the BMS group re-
spectively (p = 0.565), and they included one hematoma 
requiring transfusion and one non-flow limiting dissec-
tion in the DES group, and 3 TIAs, one hematoma with 
transfusion, one non-flow limiting dissection and one 
dissection requiring additional stent implantation in the 
BMS group. There were no ischemic strokes, myocardi-
al infarction (MI) or any death within 30 days in either 
group.
MACCE and any death were analyzed during the medi-
an follow-up period of 45.4 months (range: 1–144 months) 
in the DES group and 59 months (range: 1–150 months) 






Right VA, n (%) 79 (53.4) 118 (42.1) 0.037
Left VA, n (%) 71 (48) 162 (57.9)
Transradial approach, n (%) 10 (6.8) 16 (5.9) 0.668
Contralateral VA occlusion, n (%) 13/140 (9.3) 23/260 (8.9) 0.884
V0/V1 segment, n 148 275 0.041
Old generation DES, n (% of DES):
Sirolimus-eluting stent 14 (9.4) n/a
Paclitaxel-eluting stent 8 (5.3) n/a
Second generation DES, n (% of DES):
Everolimus-eluting stent 57 (38) n/a
Biolimus-eluting stent 35 (23.3) n/a
Zotarolimus-eluting stent 36 (24) n/a
Stainless-steel, n (%) n/a 139 (49.6)
Cobalt-chromium, n (%) n/a 123 (44)
Platinum-chromium, n (%) n/a 18 (6.4)
Stenosis severity – angio (%):
Pre-treatment, mean ± SD 86.0 ±9.7 84.1 ±9.4 0.056
Post-treatment, mean ± SD 2.7 ±5 4.3 ±6.9 0.014
Stent diameter, mean ± SD [mm] 3.4 ±0.5 4.2 ±0.8 < 0.001
Stent length, mean ± SD [mm] 12 ±3.9 11.9 ±2.7 0.323
Direct stenting, n (%) 110 (73.3) 221 (78.9) 0.279
Maximum inflation pressure, mean ± SD [atm] 11.6 ±2.4 11.7 ±2.4 0.265
Maximum post-dilatation balloon pressure, mean ± SD [atm] 16.7 ±3.2 16.2 ±3.2 0.056
Simultaneous VAS + SAS, n (%) 6 (4) 9 (6.1) 0.653
Two stents implanted to cover one lesion. Continuous data are presented as the mean ± standard deviation; categorical data are given as the count and percentage. 
VAS + SAS – vertebral and subclavian artery stenting.
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in the BMS group (p < 0.001). The observation was com-
pleted for 362 (92.3%) patients at the final outpatient fol-
low-up visit, while 30 (7.7%) patients (24 in BMS and 6 in 
DES) were lost to follow-up. As per records of the General 
Electronic Population Register by the Ministry of Interior 
and Administration Database, 18 out of the 30 ‘lost-to-fol-
low-up’ patients (16 in BMS and 2 in DES group) died. 
Overall, there were 56 (14.3%) deaths. Out of 362 pa- 
tients, acute MI was recorded in 16 (4.4%), while an isch-
emic cerebral event occurred in 10 (2.8%) patients (2 in 
DES and 8 in BMS group), including 9 with a  probable 
relation to the VA stenting territory, whereas 1 was due 
to new onset atrial fibrillation. Vertigo, dizziness and syn-
cope recurrence were noted in 41 (11.3%) patients.
Renal impairment (elevated creatinine level > upper 
limit norm (ULN)) was related to higher mortality (Fig- 
ure 2 A). No difference was detected in survival curves 
related to MI and stroke between DES vs. BMS cohorts 
(Figure 2 B). However, the all-cause mortality was the 
highest for patients in whom the old-generation DES was 
implanted (Figure 2 C).
In 373 patients who completed at least a  6-month 
follow-up period with DUS/CTA examination, 409 re-
vascularized vertebral vessels were subjected to further 
analysis (Table III). ISR/ISO exceeding 50% was suspect-
ed in 84 (22.5%) patients on DUS, and 16 (4.3%) on 
CTA. Angiography confirmed ISRs > 50% in 53 (14.2%) 
patients and ISOs in 21 (5.6%) managed conservatively. 
All patients with ISR > 70% underwent subsequent endo-
vascular treatment with either plain balloon angioplasty 
(14 patients), drug-eluting balloon (22 patients) or DES 
stent implantation (17 patients).
The overall ISR/ISO rate was 19.8% with no signif-
icant difference between DES and BMS groups (22.8% 
vs. 19.4%; p = 0.635). Out of 19 old-generation DES, 
6 (31.6%) ISRs occurred, whereas out of the 92 second-gen-
eration DES, there were 25 (27.2%) ISRs (p = 0.325).
Recurrent ISR/ISO was noted in 3 patients, subse-
quently treated with drug-coated balloon (n = 2) and 
plain balloon angioplasty (n = 1).
In the BMS group, long-term patency was obtained 
significantly more often with stainless steel (24/135, 
17.8%) and cobalt-chromium (23/121, 19%), as compared 
to platinum-chromium BMS (7/18, 38.9%), p = 0.034. 
By contrast, in the DES group, implantation of biolim-
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Figure 2. A  – Survival according to the level of 
creatinine. B – Survival related to MI or stroke.  
C – Overall survival curves
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(4/31, 12.9%), as compared to everolimus (11/52, 21.2%), 
sirolimus (3/14, 21.4%), zotarolimus (10/34, 29.4%) and 
paclitaxel (3/5, 60%), p = 0.135.
Among analyzed clinical and procedural parame-
ters (Tables III, IV), younger age was related to ISR risk, 
both in the BMS (p = 0.012) and the DES (p = 0.013) 
group, while greater stent length was associated with 
ISR only in the DES group (p = 0.024) (Table III). In the 
survival analysis, elevated C-reactive protein level above 
5  mg/l was significantly associated with ISR/ISO risk 
(p = 0.041) (Figure 3). In the BMS group, data favored 
implantation of stainless steel or cobalt chromium BMS 
over platinum-chromium BMS, while in DES group no 
independent parameter with the multivariate Cox pro-
portional hazard analysis was identified in terms of ISR 
(Table IV).











Age [years] 65 ±8 68.2 ±8.7 0.012 63.4 ±8.5 67.1 ±8.4 0.013
Men, n (%) 36 (8.8) 161 (39.3) 0.340 23 (5.6) 71 (17.3) 0.486
Women, n (%) 18 (4.4) 59 (14.4) 8 (1.9) 34 (8.3)
Time to detection of ISR/ISO, 
mean ± SD [month] 
20.5 ±21.3 n/a n/a 15.8 ±12 n/a 0.228
C-reactive protein,  
mean ± SD [mg/l]
4.14 ±4.2 3.74 ±6.59 0.103 4.43 ±3.07 2.9 ±3.41 0.334
Low-density lipoprotein, 
mean ± SD [mmol/l]
2.47 ±0.83 2.58 ±0.82 0.298 2.61 ±1.03 2.49 ±0.76 0.120
Creatinine,  
mean ± SD [μmol/l]
89.7 ±19.5 93 ±35.6 0.45 90 ±24.4 88.6 ±23.1 0.94
Glucose, mean ± SD [mmol/l] 6.03 ±1.36 6.04 ±1.57 0.088 5.44 ±0.83 6.19 ±2.1 0.59
Diabetes mellitus, n (%) 17 (31.5) 52 (23.6) 0.234 6 (19.4) 36 (34.3) 0.114
Hypertension, n (%) 54 (100) 208 (94.5) 0.265 30 (96.8) 97 (92.4) 0.387
Left vertebral artery, n (%) 32* (7.8) 127 (31.1) 0.725 16 (3.9) 50 (12.2) 0.696
Right vertebral artery, n (%) 22* (5.1) 93 (22.7) 15 (3.7) 55 (13.4)
Stent diameter,  
mean ± SD [mm]
4.22 ±0.78 4.23 ±0.76 0.32 3.41 ±0.49 3.40 ±0.54 0.23
Stent length,  
mean ± SD [mm]
11.8 ±2.1 11.9 ±2.8 0.72 13.5 ±3.1 11.6 ±4.1 0.024
Biolimus, n n/a n/a n/a 4 27 0.159
0.063#
Everolimus, n n/a n/a n/a 11 41
Zotarolimus, n n/a n/a n/a 10 24
Paclitaxel, n n/a n/a n/a 3 2
Sirolimus, n n/a n/a n/a 3 11
Stainless steel, n 24 111 0.103
0.034**
n/a n/a n/a
Cobalt-chromium, n 23 98 n/a n/a n/a
Platinum-chromium, n 7 11 n/a n/a n/a
*One patient with left and right vertebral artery ISR/ISO, **p-value for stainless steel and cobalt-chromium vs platinum-chromium BMS. #P-value for paclitaxel and 
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Figure 3. Survival without ISR/ISO according to 
the level of CRP
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Discussion
Endovascular treatment of vertebral artery origin ste-
nosis greater than 50%, in patients with PFI symptoms 
that are present despite optimal medical therapy (OMT: 
risk factor modifications, antiplatelet and statin thera-
pies), is commonly accepted, as recurrence rates of verte-
brobasilar territory ischemic strokes are high, especially 
in the first days and few weeks after the event [11, 12].
In line, stent-supported angioplasty of VAS is en-
couraged by low or very low periprocedural complica-
tion rates of death and ischemic stroke, rarely exceeding 
1–1.5% in large-volume dedicated centers. Our series 
of 428 cases showed 3 (0.7%) periprocedural TIAs, and 
no major strokes or deaths. Also, in smaller studies, the 
perioperative outcomes are good [3, 5]. E.g. in the Ver-
tebral Artery Ischaemia Stenting Trial (VIST) comparing 
risks and benefits of VAS stenting plus OMT for recently 
symptomatic VAS with OMT alone, in a group of 48 pa-
tients who received stent for extracranial VAS, 1 (2.1%) 
patient had a nonfatal stroke within 30 days of interven-
tion, with no deaths [5]. This randomized study showed 
a  non-significantly lower number of fatal and nonfatal 
stroke or TIA in the proximal VAS stenting plus OMT arm 
as compared to OMT alone (log rank p = 0.07) [5].
Controversially, the enthusiasm for endovascular 
treatment of the vertebral artery origin stenosis, in pa-
tients refractory to OMT, is somewhat limited by incon-
sistent reports concerning recurrent stenosis [3, 13]. 
The rate of significant ISR (greater than 50%) after 
either BMS or DES is extremely variable in the literature. 
After BMS use, the ISR rate can reach 48-55% and when 
DES are used it can reach 63% [3, 13–16]. 
In the Eberhardt et al. review of 300 interventions for 
proximal VAS, ISR occurred in 26% of cases after a mean 
of 12 months (range: 3–25 months) [17]. In this context, 
our long-term results are good, as the ISR rate was 19.8% 
for the whole study group, with no significant differences 
in crude ISR rates between the BMS and the DES groups.
Nevertheless, recently, a rising number of case series 
support the use of DES in endovascular treatment of VAS, 
which relates to the reduced rate of ISR/ISO, as compared 
to BMS in long-term follow-up [14, 18].
The expectation from DES is a decrease in ISR through 
inhibition of smooth muscle and endothelial prolifera-
tion. Although experience described in the coronary lit-
erature largely supports such practice, DES I  in cardiac 
procedures have been found to be associated with clot 
formation in some cases, resulting in thrombosis at the 
stent site [10, 19]. Recently, second generation DES were 
introduced with the scope to overcome the limitations of 
the first generation DES.
Consistently, the average ISR rates in patients with 
VAS were calculated at 29.6% (range: 3–55%) from 12 
case series with BMS use and at 14.1% (range: 0–63%) 
from 7 case series with DES use [3].
Furthermore, in one reported study, BMS (HR = 2.02; 
p < 0.05) was even independently associated with an in-
creased risk of ISR [20].
Our data indicate large variations between ISR rates 
and type of the stent implanted within the analyzed 
subgroups. In the BMS group, we observed significant-
ly higher rates of ISR when a platinum-chromium stent 
was used (38.9%), as compared to stainless steel (17.8%) 
and cobalt-chromium (19%) BMS, whereas in the DES 
group the best outcome was noted for the biolimus stent 
(12.9%), everolimus (21.2%), and sirolimus (21.4%), as 
compared to zotarolimus (29.4%) and paclitaxel (60%) 
coated stents. 
In contrast, Song et al. found ISR of 20.2% (19/94) 
at 1 year for stainless steel and cobalt-chromium BMS, 
Table IV. Factors associated with in-stent restenosis identified by univariate and multivariate Cox proportional 
hazard analysis
Parameter Univariate Cox proportional 
hazard analysis
HR (95% CI); p-level
Multivariate Cox proportional 
hazard analysis
HR (95% CI); p-level
Age 0.96 (0.94–0.99); 0.002 0.96 (0.92–0.99); 0.05
Hyperlipidemia 0.85 (0.27–2.69); 0.78 –
Hypertension 0.58 (0.08–4.15); 0.58 –
Intervention on RVA vs. LVA 0.92 (0.59–1.42); 0.69 –
Stent diameter 5.58 (0.01–17.2); 0.912 –
Stent length 1.43 (0.01–8.28); 0.988 –
CRP 1.01 (0.98–1.04); 0.36 –
Stent type:
Stainless steel/cobalt chromium vs. platinum-chromium BMS 0.22 (0.10–0.78); 0.001 0.28 (0.13–0.64); 0.002
Paclitaxel/zotarolimus vs. biolimus/everolimus DES 0.55 (0.27–1.15); 0.114 –
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compared to 6.3% (7/112) in sirolimus (n = 73) and pa-
clitaxel-coated (n = 52) DES I  [21]. The stent type may 
also matter during the intracranial interventions in the 
vertebrobasilar territory [22].
In Langwieser’s study, the ISR was 23%, concern-
ing the stent type, self-expandable BMS were associat-
ed with a  significant higher ISR rate compared to bal-
loon-expandable stents (p = 0.012), and although not 
statistically significant, there was a lower ISR rate in DES 
compared to BMS (p = 0.068) [23].
As most case series with stenting of VAS include pa-
tients with either intracranial and extracranial VAS, as 
well as using different types of stents, data on the rela-
tionship between particular stent type and ISR risk are 
missing or not available [24]. 
Again, more experience is available in the coronary 
territory; e.g. a meta-analysis of Navarese et al. showed 
that everolimus DES reduced the odds of repeat revas-
cularization compared with paclitaxel-eluting stents, but 
zotarolimus-Endeavor stents increased the odds com-
pared with sirolimus-eluting stents [9].
The major limitation in the DES choice is the former 
availability of stent diameters present on the market. Most 
DES suffered from size limitations (up to 4 mm), and for 
that reason we were not able to randomize patients to 
BMS and DES groups for direct head-to-head comparisons. 
However, in both our present and a  previously reported 
study, although DES had mean lower diameter as com-
pared to BMS, this fact had no impact on the ISR rates [25]. 
This issue seems relevant, as some studies indicate 
that stent diameter is an important indicator of ISR risk 
[26, 27]. E.g. in the study of Zhou et al., ISR rates were 
found to be associated with tortuosity of extracranial VA 
and lower stent diameter [26]. This is in line with our pre-
vious findings concerning carotid and subclavian artery 
stenosis, where stent diameter along with inflammatory 
status, and patient age were independently associated 
with ISR [28–31].
In contrast, in the study of Song et al., stent diame-
ter and length were not associated with ISR risk, but the 
mean stent diameter was quite large (BMS: 4.4 ±0.7 mm 
vs. DES I: 4.1 ±0.8  mm), whereas diabetes (HR = 2.66, 
p = 0.022) and smoking (HR = 3.85, p = 0.015) predicted 
the need for repeated revascularization [21]. In our study 
stainless steel and cobalt chromium BMS was associated 
with IRS risk reduction as compared to platinum-chro-
mium BMS implantation, while younger patient age and 
stent length in the DES group increased the risk of ISR/
ISO. In the study by Werner et al. of vertebral artery origin 
lesions, stent compression/recoil was found by angiog-
raphy in 11 (39%) of the patients who received a pacl-
itaxel-eluting stent at a  mean follow-up of 16 months, 
which limited the long-term outcome [32].
The constant development of drugs released by stents 
and type of material allow better long-term outcomes to 
be achieved compared to old-generation stents.
One obvious limitation of the study is the lack of pa-
tient randomization to the BMS and the DES. However, 
as the time period of study enrollment is long (since year 
2003), DES were not available at the beginning. Later DES 
of a limited diameter were available (less than 4 mm in 
diameter), not suitable for larger vertebral arteries. For 
that reason a direct head-to-head comparisons between 
DES and BMS is not possible. We observed differences 
between stent type and IRS prevalence, but the lack of 
statistical significance between DES subtypes is probably 
attributable to the low numbers of some stents.
Conclusions
Both DES and BMS vertebral artery stenting can be 
performed safely with high technical success and a low 
periprocedural complication rate. No significant differ-
ence in ISR/ISO between DES and BMS was noted in the 
long-term follow-up, but in the subgroups analysis pacl-
itaxel DES as well as platinum-chromium BMS had the 
highest ISR/ISO rates.
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